Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bethanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bethanidine SCHEMBL29390473 | 1.00 | KMT2A (0.43) | KMT2ASMN1; SMN2POLBKDM4ETSHR | |
| Bethanidine SCHEMBL7530034 | 1.00 | KMT2A (0.43) | KMT2ASMN1; SMN2POLBKDM4ETSHR | |
| Bethanidine SCHEMBL122035 | 1.00 | KMT2A (0.43) | KMT2ASMN1; SMN2POLBKDM4ETSHR | |
| Bethanidine SCHEMBL34432 | 0.92 | ALOX12 (0.48) | KMT2ASMN1; SMN2POLBKDM4EALDH1A1 | |
| Bethanidine SCHEMBL34434 | 0.92 | ALOX12 (0.48) | KMT2ASMN1; SMN2POLBKDM4EALDH1A1 | |
| Bethanidine SCHEMBL34433 | 0.92 | ALOX12 (0.48) | KMT2ASMN1; SMN2POLBKDM4EALDH1A1 | |
| Bethanidine SCHEMBL11505129 | 0.90 | MAPT (0.50) | KMT2ASMN1; SMN2POLBKDM4EALDH1A1 | |
| Meobentine SCHEMBL121188 | 0.82 | ALDH1A1 (0.50) | KMT2ASMN1; SMN2KDM4EALDH1A1CA2 | |
| Meobentine SCHEMBL1650297 | 0.82 | ALDH1A1 (0.50) | KMT2ASMN1; SMN2KDM4EALDH1A1CA2 | |
| SCHEMBL11840901 | 0.78 | ALOX12 (0.48) | KMT2ASMN1; SMN2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114887074-A | Antibody-drug conjugates comprising modified antibodies | 阿特根公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114588252-A | Composition for relieving vaginal atrophy and xerosis and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2022-06-07 | — | — | CN | claimed |
| CN-105062951-A | Induction liquid, induction medium and method for induction culture of mesenchymal stem cells | SHENZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD | 2015-11-18 | — | — | CN | claimed |
| CN-105062952-A | Method for transformation of mesenchymal stem cells into islet cells | SHENZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD | 2015-11-18 | — | — | CN | claimed |
| CN-104257690-A | Stem cell preparation for treating diabetes mellitus and preparation method of preparation | JIANGSU STEM CELL OSDBIO CO LTD | 2015-01-07 | — | — | CN | claimed |
| CN-102618491-B | Culture solution for inducing mesenchymal stem cells to differentiate into islet-like cells, and inducing method and application of culture solution | UNION STEMCELL & GENE ENG CO | 2014-04-09 | — | — | CN | claimed |
| CN-101384275-B | Dissolution aid comprising biguanide for oral peptide delivery | AXCESS LTD | 2012-11-28 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| CN-102618491-A | Culture solution for inducing mesenchymal stem cells to differentiate into islet-like cells, and inducing method and application of culture solution | UNION STEMCELL & GENE ENG CO | 2012-08-01 | — | — | CN | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1209183-C | Wet granulation method for generating sulfur granules | AIRBORNE IND MINERALS INC (CA) | 2005-07-06 | — | — | CN | claimed |
| US-6884792-B2 | Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2005-04-26 | — | — | US | claimed |
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2003-06-26 | — | — | US | claimed |
| CN-1392772-A | Animal showing schizophrenia-like abnormality in coagnitive behaviors and method of construction same | JAPAN GOVERNMENT (JP) | 2003-01-22 | — | — | CN | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| CN-1297372-A | Wet granulation method for generating sulfur granules | AIRBORNE IND MINERALS INC (CA) | 2001-05-30 | — | — | CN | claimed |
| CN-1111910-A | Mammamodulin, a hormone-independent mammary tumor cells specific protein | HOFFMANN LA ROCHE (CH) | 1995-11-15 | — | — | CN | claimed |
| WO-1994016692-A1 | METHOD AND COMPOSITIONS FOR TREATING ANOESTRUS | THE MINISTER OF AGRICULTURE, FISHERIES AND FOOD IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1994-08-04 | — | — | WO | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | TNNT2, TNNI3, FABP3 | KMT2A 4464/4885SMN1; SMN2 1650/4885POLB 4779/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | KMT2A 2686/4885SMN1; SMN2 1924/4885POLB 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.